Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company’s web site at www.santarus.com.
- 17 years ago
QualityStocks
Santarus, Inc. (NASDAQ: SNTS)
Tags Rodman & Renshaw
Related Post
-
Building the Future of U.S. Mineral Independence: Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Highlights Vast Resource Potential at Alaska’s Ambler Mining District
Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include…
-
When Major Miners Pivot: What Hecla’s Nevada Renaissance Means for Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) and Adjacent Exploration Ground
Disseminated on behalf of Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) and may include paid advertising.…
-
Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Positioned for Platinum Supply Crunch
Disseminated on behalf of Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) and may…